ReviewEuropean journal of medical research2025
Research advances of matrix metalloproteinases family in uveal melanoma.
Review in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
As a zinc-containing family of endopeptidases, matrix metalloproteinases (MMPs) are not only the main hydrolytic enzymes for the degradation of extracellular matrix and basement membrane, but also the main protein family involved in tumor metastasis. In addition to playing a key role in normal physiological processes, previous studies have shown that MMPs are also important in tumorigenesis and development, including but not limited to promoting epithelial-mesenchymal transformation, angiogenesis, and inducing the expression of adhesion molecules. Therefore, as a potential diagnostic marker and therapeutic target, the relationship between MMPs and carcinogenesis and metastasis has also been widely studied. As the most frequent intraocular malignant tumor in adults, uveal melanoma (UM) poses a great threat to patients' visual acuity and lives. MMPs contribute to UM progression by promoting extracellular matrix degradation, tumor microenvironment remodeling, and metastasis. Clinical and bioinformatic studies have identified MMPs as both prognostic biomarkers and potential therapeutic targets in UM, supported by their association with tumor characteristics, immune-related phenotypes, and the expression of endogenous inhibitors like TIMPs. This article comprehensively reviews the expression profiles and clinical significance of MMPs in UM, highlighting their roles in tumor progression, metastasis, and potential as therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.